Clinical trial · Interventional
Study of the Angiogenesis by PET/CT in Patients With Lymphoma
Study of the Angiogenesis Measured by PET/CT With 18F-RGD-K5 in Patients With Lymphoma : a Preliminary Study
NCT02490891CI-TRIAL-00100011RGDLymphomecompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of the study is to measure tumoral angiogenesis modifications by RGD-K5 PET/CT before and after 2 cycles of chemotherapy in patients with lymphoma and a large tumoral mass
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| RGD K5 PET scan | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET scan with RGD K5 imaging
- description
- PET scan with RGD K5 tracer will be performed before and after two cycles of chemotherapy
- interventionNames
- Device: RGD K5 PET scan
Primary outcomes (1)
- measure
- Measure of angiogenesis with RGD K5 PET scan
- timeFrame
- 3 months
- description
- Measure of fixation, metabolic volume and angiogenic volume with RGD K5 traver
Secondary outcomes (3)
- measure
- Measure of angiogenic volume with K5 tracer
- timeFrame
- 3 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or Female * Age ≥ 18 years old * OMS ≤ 1 * Histological diagnosis of diffuse large B-cell lymphoma what ever the subtype * Presence of measurable tumor with at least a node mass superior to 3 centimeters * Stage I to IV * Inform consent signed Exclusion Criteria: * Primary cerebral lymphoma * Absence of fixing on FDG-PET exam * Pregnant , child bearing, breast feeding or without effective contraception method woman * Hypersensitivity to RGD-K5 * Hypersensitivity to FDG * Poorly controlled diabètes (glycemia ≥ 10 millimoles/liter) * Neoplastic disease (less than 2 years or in progression)
References
Publications (0)
Data not yet available
No reference posted for this study.